

MEMBERS

BRIAN MAIENSCHIN, VICE CHAIR
ROB BONTA
AUTUMN BURKE
JAMES GALLAGHER
MONIQUE LIMÓN
KEVIN MCCARTY
ADRIN NAZARIAN
JIM PATTERSON
SHARON QUIRK-SILVA
SEBASTIAN RIDLEY-THOMAS
FREDDIE RODRIGUEZ
MIGUEL SANTIAGO
TONY THURMOND
MARIE WALDRON



CHIEF CONSULTANT
ROSIELYN PULMANO

CONSULTANTS
LARA FLYNN
KRISTENE MAPILE
PAULA VILLES CAZ
JUDY BABCOCK

LEAD SECRETARY
PATTY RODGERS

SECRETARY
MARSHALL KIRKLAND

INFORMATIONAL HEARING

Impact of Rising Drug Costs on Public and Private Payers

Tuesday, February 14, 2017 ♦ 1:30 p.m. – 5:00 p.m.

State Capitol ♦ Room 4202

AGENDA

I. Impact on Public Programs

♦ **Medi-Cal**

- ♦ Jennifer Kent, *Director, Department of Health Care Services*

♦ **CalPERS**

- ♦ Kathleen Donneson, *Chief, Health Plan Administration Division, CalPERS*
- ♦ Richard KP Sun, M.D., *Medical Consultant II, CalPERS*

♦ **Department of General Services**

- ♦ Ben Johnson, *Fiscal and Policy Analyst, Legislative Analyst Office*

♦ **Los Angeles County**

- ♦ Amy Gutierrez, *Chief Pharmacy Officer, Los Angeles County Department of Health Services*

II. Impact on Private Payers

♦ **Hospitals**

- ♦ Scott Evans, *CEO, Sharp Grossmont Hospital and Head of Sharp System Pharmacy*

♦ **The Kaiser Permanente Model**

- ♦ Ambrose Carrejo, PharmD, *Pharmaceutical Contracting Leader, Kaiser Permanente*

♦ **Employers**

Large Employer Group/Unions

- ♦ Mario Yedidia, *Senior Analyst, UNITE HERE International Union*

Small Business

- ♦ Mark Herbert, *California Director, Small Business Majority*

♦ **Health Plans/Health Insurers**

- ♦ Nick Louizos, *Vice-President, Legislative Affairs, California Association of Health Plans*

III. Emerging Policy Issues

- ♦ Jeffrey S. Hoch, Ph.D., *Professor, Department of Health Sciences, Associate Director, Center for Healthcare Policy and Research, University of California, Davis*

IV. Response from Pharmaceutical Manufacturers

- ♦ Kristin Manzolillo, *Senior Director, Global Policy, Pfizer, Inc*

V. Response from Pharmaceutical Benefit Managers

- ♦ John Jones, R.Ph., J.D., FAMCP, *Health Policy Consultant, Pharmaceutical Care Management Association*

VI. Public Comments